Rainbow Medical Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Rainbow Medical Ltd.
The field of neuromodulation has produced numerous start-ups and a decent amount of fundraising activity over the past six years, but exits are scarce.
Sorin’s $20 million investment will help Respicardia continue the U.S. pivotal trial of the remedē implantable phrenic nerve stimulator for sleep apnea and give Sorin exclusive rights to distribute the device in select European countries, where it has a CE mark but has yet to be launched.
Device companies kicked off 2013 by raising $1.1 billion via 45 transactions; the only device M&A transaction in Q1 to exceed the billion-dollar mark was Cardinal Health Inc.’s $2.07 billion acquisition of AssuraMed. Diagnostics firms began 2013 by raising a total of $286 million in the opening quarter, a 46% improvement over Q4 2012’s tally.
Emerging technologies in peripheral nerve stimulation are expected to play a pivotal role in opening up new markets and driving growth in the neuromodulation device market in the years ahead. As a result, the pipeline is rich with products designed to address a growing number of patients with long-term pain and other chronic conditions, many of whom have no other treatment options.
- Medical Devices
- Consumables, Central Supplies
- Implantable Devices
- Infection Control-Sterilization
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Radiofrequency Devices
- Rehabilitation Equipment and Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- Affix Medical
- BlueWind Medical
- ChroniSense Medical
- Enopace Biomedical
- Fibro Control
- ProstaPlant Urology Systems
- Pythagoras Medical
- Roboscopy Medical
- Slender Medical
- Vascular Dynamics